Skip to Main Content

Phase 3 Alogliptin Pediatric Study

Conditions

Diabetes Mellitus - Type 2

Phase III

What is the purpose of this trial?

Brief Summary:

This study will evaluate the efficacy and safety of alogliptin 25 mg once daily (QD) compared to placebo when administered as monotherapy, or when added onto a background of metformin alone, insulin alone, or a combination of metformin and insulin in pediatric participants 10 to 17 years of age with type 2 diabetes mellitus (T2DM).

  • Trial with
    Takeda Pharmaceuticals, America, Inc.
  • Start Date
    08/09/2018
  • End Date
    06/11/2021

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/15/2021
  • Study HIC
    #2000022953